Actively Recruiting
Evaluating Belantamab Alone and in Combination Treatments for Multiple Myeloma Safety and Activity
Led by GlaxoSmithKline · Updated on 2026-08-19
123
Participants Needed
44
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are investigating the safety, tolerability, and clinical activity of belantamab, alone and in combination with other drugs, in participants with multiple myeloma. The study is divided into three parts Part 1 evaluates escalating doses of belantamab in participants with refractory multiple myeloma who have had at least three prior therapies Part 2 assesses different doses of belantamab combined with belantamab mafodotin in a similar participant group Part 3 studies belantamab combined with a pomalidomide-dexamethasone standard treatment in participants who have received at least one prior therapy including lenalidomide. This phase 12 open-label trial aims to explore these treatments in participants with advanced disease. Participants receive belantamab monotherapy, belantamab with belantamab mafodotin, or belantamab with pomalidomide and dexamethasone, depending on study part. In Parts 1 and 2, treatment continues until disease progression, after which participants may opt for belantamab mafodotin alone. The study uses a sequential design with randomized allocation. Each treatment is administered as specified, and dosing adjusts according to safety and tolerability evaluations. During the study, participants undergo regular monitoring for adverse events, dose-limiting toxicities, and changes in laboratory and vital signs up to 52 months. Specific assessments include ocular event severity, response rates, and pharmacokinetic measurements. The study also tracks immunogenicity by measuring anti-drug antibodies. Researchers evaluate clinical activity through overall response rates and disease progression metrics while ensuring participant safety through ongoing evaluations and compliance monitoring.
CONDITIONS
Brief Title
A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments
Research Team
U
US GSK Clinical Trials Call Center
E
EU GSK Clinical Trials Call Center
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here